It is the company's sole product and the main brand used for Cryolipolysis.

An early prototype was created to advance cryolipolysis studies being done on pigs in 2008.

Cryolipolysis: refers to a medical device used to destroy fat cells.

In Europe cryolipolysis machines are used in aesthetic clinics and spas.

Zeltiq uses controlled cooling to target and eliminate fat cells, a process called selective cryolipolysis.

Cryolipolysis makes use of a powerful vacuum which adds to the inflammatory response by drawing blood up to the surface layers of the skin.

As of 2013, clinical trials have found that Cryolipolysis is moderately effective and has mostly mild and temporary side-effects.

Non-surgical liposuction techniques use laser energy, radiofrequency, ultrasound or cold (cryolipolysis) to reduce fat.

Its sole product, CoolSCulpting, is "the main Cryolipolysis device available in the market".

WHAT CoolSculpting is the original form of cryolipolysis.

Because there is no suction involved, terms such as laser lipolysis, cryolipolysis or body contouring are preferred to non-surgical liposuction.

A single 45-minute cryolipolysis freezing treatment - similar to the one Made in Chelsea's Binky Felstead had may also be given.

In September 2010, the US Food and Drug Administration approved the cryolipolysis device and procedure.

In September 2009, Zeltiq received EU CE Mark approval for their cryolipolysis device.

Common methods used include low-level laser therapy (LLLT), cryolipolysis, radiofrequency energy, suction massage, and high-frequency focused ultrasound.

Based on the premise that fat cells are more easily damaged by cooling than skin cells, Cryolipolysis was developed to apply low temperatures to tissue via thermal conduction.

ZELTIQ Aesthetics is a public company based in Pleasanton, California that markets and licenses the CoolSculpting cryolipolysis procedure.

Zeltiq obtained FDA approval in 2010 for cryolipolysis of the flanks and additional approval in 2012 for cryolipolysis of the abdomen.

CoolSculpting is the newest FDA-cleared development that CoolSculpting manufacturer ZELTIQ Aesthetics refers to as Cryolipolysis.

It is based on cryolipolysis, a method of controlled cold exposure that causes an inflammatory response in fat cells, resulting in gradual cell death and consumption by macrophages, without causing damage to other tissues.

Some cryolipolysis devices have a pair of applicators that can be used simultaneously reducing the overall treatment time when treating corresponding areas such as the sides of the stomach, back of legs and flanks.

The initial Cryolipolysis research and patents were originated at The Wellman Center by Dr. Dieter Manstein and Dr. R. Rox Anderson.

The decree was revised on 17 February 2012, distinguishing invasive techniques, which remain forbidden, from permitted non-invasive techniques; laser, RF, ultrasound and cryolipolysis that did not penetrate the skin became legal, and injection lipolysis and mesotherapy remained illegal.

Various lipolysis techniques ("actes de lyse adipocytaire à visée esthétique") including injection lipolysis, RF, laser, ultrasound, and cryolipolysis were forbidden in France by a decree of the French Public Health Authority on 11 April 2011.